If/when Ryoncil is approved in the US then the commercial revenue/sales are very real.
I think the market is now factoring in that this is HIGHLY likely to occur.
As such, analysts need to factor in these numbers into their Valuation and this is were the share price is experience a re-rate.
Not only will there be sales, but there will also be new positive light on the company for its mechanism of action which is basically paracrine signalling across a host of diseases.
A partner for EU is also now very real for Ryoncil and for a market of another $300m p.a in the EU this could equate to an excellent partnership deal.
MSB Trading - 2020, page-862
-
- There are more pages in this discussion • 22,299 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $3.961M | 3.594M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 67283 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 7442 | 2 |
View Market Depth
| Last trade - 13.57pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |